No Data
No Data
ACCUSTEM SCIENCES INC | 10-Q: Quarterly report
AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership
LONDON and PHOENIX, July 17, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, and EmeritusDX, a rapidly
AccuStem Sciences, Inc. Extends and Broadens Partnership With Instituto Europeo Di Oncologia (IEO) Enabling Its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrence LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE) -- AccuStem
Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc.
BALTIMORE, MD / ACCESSWIRE / June 20, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new re
AccuStem Sciences, Inc. Announces Collaboration Agreement With University Hospitals
AccuStem Sciences, Inc. (OTCQB: ACUT) today announced the establishment of a joint clinical collaboration agreement with University Hospitals.
AccuStem Announce Strategic Clinical and Operational Partnership
LONDON and PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, today annou
No Data